10x GenomicsTXG +2.85%62 Gross Margin % is 70.39% as of Mar. 2026, which is 8% below its 10-year median of 76.69. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $19.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 631 Healthcare Providers & Services companies, 10x Genomics ranks better than 78.61% on this metric.
10x Genomics Inc gross margin has been in long-term decline. The average rate of decline per year is -4.4%.
The historical rank and industry rank for 10x Genomics's Gross Margin % or its related term are showing as below:
TXG'
s Gross Margin % Range Over the Past 10 Years
Min: 66.15 Med: 76.69 Max: 85.14
Current: 69.6
During the past 9 years, the highestGross Margin % of 10x Genomics was 85.14%. The lowest was 66.15%. And the median was 76.69%.
TXG's Gross Margin % is ranked better than 78.61% of 631
companies
in the Healthcare Providers & Services industry
Industry Median: 40.09
vs TXG: 69.60
10x Genomics had a gross margin of 70.39% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for 10x Genomics was -4.40% per year.
10x Genomics (NAS:TXG) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
10x Genomics had a gross margin of 70.39% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
10x Genomics Gross Margin % Related Terms
10x Genomics Gross Margin % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
10x Genomics (TXG) has a Gross Margin % of 70.39% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on 10x Genomics and its competitors. This is near median its historical median of 76.69. Over the past decade, 10x Genomics' Gross Margin % has ranged from 66.15 to 85.14. According to the industry distribution chart, 10x Genomics ranks #135 out of 631 companies in the Healthcare Providers & Services industry, placing it in the top 21.4%.
Is 10x Genomics' Gross Margin % too high?
10x Genomics' current Gross Margin % of 70.39% is near median its 10-year median of 76.69. Over the past 10 years, this metric has ranged from a low of 66.15 to a high of 85.14. The Healthcare Providers & Services industry median Gross Margin % is 40.09. 10x Genomics' value of 70.39% is 75.6% above this industry median. Based on the distribution chart, 10x Genomics ranks #135 out of 631 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Gross Margin % compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #135 out of 631 companies for Gross Margin %. This places 10x Genomics in the top 21% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 40.09. 10x Genomics' value of 70.39% is 75.6% above this benchmark. Historically, 10x Genomics' own Gross Margin % has ranged from 66.15 to 85.14 over the past decade. While the company's 10-year median is 76.69 vs. the industry median of 40.09, 10x Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.09, based on 631 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Gross Margin % of 70.39% is 75.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Gross Margin % is 70.39%, which is near median its own 10-year median of 76.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.00, compared to a current price of $36.70 — trading 93.2% above its estimated fair value. The current Gross Margin % is 70.39%, which is near median its 10-year median of 76.69 and 75.6% above the Healthcare Providers & Services industry median of 40.09. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For 10x Genomics (TXG), the current Gross Margin % is 70.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $36.70 is trading 93.2% above its estimated GF Value™ of $19.00.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Gross Margin %: 70.39% (near median its 10-year median of 76.69)
GF Value™: $19.00 vs. price of $36.70 (93.2% above fair value)
Industry Position: 75.6% above the Healthcare Providers & Services median (#135 of 631)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
